Skip to main content
SpringerPlus

Table 2 Baseline patient and tumor characteristics for patients with pre-testing recommendations of hormonal therapy alone vs. chemohormonal therapy

From: Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results

 

Physician’s treatment recommendation pre-Oncotype DX testing

Hormonal therapy (n = 78)

Chemohormonal therapy (n = 33)

Age a

  

 Mean (SD), years

57.4 (9.0)

53.8 (9.1)

 Median (range), years

57.5 (37-76)

55 (35-72)

Tumor size b

  

 Mean (SD), mm

14.8 (5.4)

20.1 (9.1)

 Median (range), mm

14 (6-35)

19 (8.5-55)

Nodal status, c n (%)

  

 Node negative

71 (94.7)

19 (63.3)

 Node positive

4 (5.3)

11 (36.7)

Tumor grade, d n (%)

  

 1

14 (20.6)

1 (3.2)

 2

42 (61.8)

20 (64.5)

 3

12 (17.7)

10 (32.3)

Type of surgery, e n (%)

  

 Lumpectomy

71 (91.0)

22 (66.7)

 Mastectomy

7 (9.0)

11 (33.3)

Recurrence score result f

  

 Mean (SD)

22.5 (3.5)

24.1 (4.0)

 Median (range)

22 (18-29)

24 (18-30)

  1. SD standard deviation.
  2. aP = 0.056 (t-test for comparing means).
  3. bP = 0.0037 (t-test for comparing means). Tumor size information was unavailable for 1 patient in the chemohormonal therapy group.
  4. cP = 0.00013 (Fisher’s exact test). Nodal status information was unavailable for 3 patients in the hormonal therapy group and 3 patients in the chemohormonal therapy group.
  5. dP = 0.043 (Chi-squared test). Grade information was unavailable for 10 patients in the hormonal therapy group and 2 patients in the chemohormonal therapy group.
  6. eP = 0.0015 (Chi-squared test).
  7. fP = 0.047 (MWW test).
Back to article page